Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 6/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718374 | 0.86 | HTR2A (0.71) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| Tert-Butyl Formate SCHEMBL27916987 | 0.84 | SLC6A4 (0.50) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL1971111 | 0.83 | HTR2A (0.76) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL24452687 | 0.83 | GPR84 (0.69) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL3181757 | 0.83 | GPR84 (0.69) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL27929621 | 0.82 | GPR84 (1.00) | GPR84SLC6A4HTR2ATRPM8ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30396693 | 0.81 | HTR2A (0.73) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| Hydrochloric Acid SCHEMBL2537521 | 0.81 | HTR2A (0.73) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL16540596 | 0.80 | SLC6A4 (0.67) | GPR84SLC6A4HTR2ATRPM8HTR2C | |
| SCHEMBL5657225 | 0.80 | SLC6A4 (0.67) | GPR84SLC6A4HTR2ATRPM8HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376500-B2 | 1-(INDOL-3-YLALKYL)ALKYLPIPERIDIN-4 -YL)-3H-QUINOLIN-4-ONE, FOR EXAMPLE; ALPHA1A/ B-RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; UROGENITAL DISORDERS; BENIGN PROSTATIC HYPERTROPHY; ANALGESICS FOR INFLAMMATORY, NEUROPATHY, CANCER, | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | CLARK ROBIN DOUGLAS (US) | 2001-12-13 | — | — | US | disclosed |
| US-6258819-B1 | BIOLOGICAL RECEPTORS, ANTIINFLAMMATORY AGENTS, BENIGN PROSTATE AND SIDE EFFECT REDUCTION | SYNTEX (U.S.A.) LLC | 2001-07-10 | — | — | US | disclosed |
| WO-2001010860-A2 | QUINAZOLINONE AND AZAQUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | ADRA2B, ADRA1D, ADRA1B | GPR84 269/4885SLC6A4 678/4885HTR2A 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.